ClinicalTrials.gg

Program

WRN Inhibitor EIK1005

Its studies are mostly in Endometrial Neoplasms, led by Eikon Therapeutics.

Furthest: phase 2, since Nov 10, 20251 company-led study, 1 open or runningNext primary completion: Mar 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eikon Therapeutics11 open or runningphase 2since Nov 10, 2025Nov 10, 2025Mar 2029phase 2 · NCT07262619

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2025First study: phase 2 study in Endometrial NeoplasmsFirst studyNCT07262619 · 160 planned · United States, Australia, Austria and more

Ahead

  1. Mar 2029Primary completion: phase 2 study in Endometrial NeoplasmsNCT07262619

TargetBeta

WRN →read by rule
“An orally bioavailable and selective inhibitor of the Werner syndrome ATP-dependent helicase (WRN), ”NCIt, by rule

Other programs on WRN

ProgramCompanyFurthest phaseStudies
WRN Inhibitor RO7589831ruleBayerphase 22
WRN Inhibitor GSK4418959ruleGlaxoSmithKlinephase 21
WRN Inhibitor NDI-219216rulenimbus-wadjet-incphase 21
WRN Inhibitor MOMA-341rulemoma-therapeuticsphase 11
WRN Inhibitor AMG 436ruleAmgenphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07262619Endometrial Neoplasms · United States, Australia, Austria and more2RecruitingMar 2029160

How it is read

Names in the registry

  • “EIK1005”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.